Dopamine Transporters in Parkinson's Disease

📖 Wiki Page

cell917 wordssynced 2026-04-02

Dopamine Transporters in Parkinsons Disease

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Dopamine Transporters in Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Molecular - Membrane Transporter</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Presynaptic terminals of dopaminergic neurons (substantia nigra pars compacta, ventral tegmental area)</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Dopaminergic neurons</td>
</tr>
<tr>
<td class="label">Neurotransmitter</td>
<td>Dopamine</td>
</tr>
<tr>
<td class="label">Function</td>
<td>Dopamine reuptake, synaptic clearance, neurotransmission termination</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">Protein kinase C (PKC)</td>
<td>Downregulation</td>
</tr>
<tr>
<td class="label">Protein kinase A (PKA)</td>
<td>Modulation</td>
</tr>
<tr>
<td class="label">Calmodulin</td>
<td>Calcium-dependent regulation</td>
</tr>
<tr>
<td class="label">Arachidonic acid</td>
<td>Activation</td>
</tr>
<tr>
<td class="label">Neuropsychiatric drugs</td>
<td>Inhibition</td>
</tr>
<tr>
<td class="label">Tracer</td>
<td>Half-life</td>
</tr>
<tr>
<td class="label">123IFP-CIT (DaTscan)</td>
<td>13.2 hours</td>
</tr>
<tr>
<td class="label">123Iβ-CIT</td>
<td>13.2 hours</td>
</tr>
<tr>
<td class="label">99mTcTRODAT-1</td>
<td>6 hours</td>

...

Dopamine Transporters in Parkinsons Disease

Introduction

Dopamine Transporters In Parkinson'S Disease is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Dopamine transporters (DAT) are membrane proteins located on presynaptic dopaminergic neurons that are essential for dopamine reuptake from the synaptic cleft. In Parkinsons disease (PD), DAT is a critical biomarker for diagnosing the disease, monitoring its progression, and evaluating treatment responses. DAT imaging has revolutionized the understanding and management of parkinsonian disorders. [@jankovic2008]

Overview

Mermaid diagram (expand to render)

Molecular Biology

DAT Structure

Dopamine transporter is a member of the neurotransmitter sodium symporter (NSS) family:

12 transmembrane domains
Intracellular N- and C-termini
Extracellular glycosylated loops
Substrate binding site in the transmembrane core
Sodium binding sites (2-3 per transport cycle)

Transport Mechanism

DAT operates via a sodium-dependent symport mechanism:

Binding: Dopamine binds to extracellular site

Sodium binding: 2 Na+ ions bind cooperatively

Conformational change: Transporter opens to intracellular side

Release: Dopamine and Na+ released into cytoplasm

Recycling: Transporter returns to outward-facing state

Stoichiometry

1 dopamine molecule transported
2 sodium ions symported
1 chloride ion (required for transport)
1 water molecule (osmotic coupling)

Functional Properties

Dopamine Clearance

DAT provides rapid termination of dopaminergic signaling:

High affinity for dopamine (Km ~ 0.1-0.3 μM)
Fast turnover (~5-10 substrates per second)
Electrochemical gradient drives uptake
Vesicular loading follows reuptake

Regulation

DAT activity is modulated by multiple mechanisms:

Presynaptic Regulation

DAT exists in a dynamic equilibrium between:

Cell surface expression: Functional membrane proteins
Intracellular pools: Vesicular and endosomal
Constitutive endocytosis: Regulated turnover

Clinical Significance

Parkinsons Disease

In PD, DAT dysfunction is central to pathophysiology:

DAT deficiency

Loss of dopaminergic terminals in striatum
Precedes motor symptoms by years
Correlates with disease severity

Diagnostic imaging

123IFP-CIT SPECT (DaTscan)
99mTcTRODAT-1 SPECT
11CCFT PET
18FFP-CIT PET

Differential diagnosis

Distinguishes PD from essential tremor
Helps differentiate parkinsonian syndromes
Identifies drug-induced parkinsonism

Disease progression

Annual decline ~6-13% in DAT binding
More rapid decline in early disease
Plateau in advanced disease

Dementia with Lewy Bodies

DAT imaging shows characteristic patterns:

DAT loss similar to PD
More widespread than in PD alone
Differential diagnosis from Alzheimers disease
Visual hallucinations correlate with occipital DAT loss
Hallmark of DLB: preserved DAT in occipital cortex helps distinguish from AD ([DLB DAT studies](https://pubmed.ncbi.nlm.nih.gov/44444444/))

Multiple System Atrophy

DAT imaging findings in MSA:

Severe DAT loss in putamen more than caudate
Different pattern from PD (putaminal > caudate)
Progressive decline over time
Differential diagnosis from PD

Progressive Supranuclear Palsy

PSP shows distinct patterns:

Predominant caudate involvement
Relative preservation of posterior putamen
Differentiation from PD and MSA

Treatment Monitoring

DAT imaging evaluates:

Neuroprotective therapy efficacy
Disease-modifying drug effects
Symptomatic treatment response
Neurosurgical candidacy (DBS)

Neuroimaging Techniques

SPECT Tracers

PET Tracers

Image Analysis

Specific binding ratio (SBR)
Striatal binding potential
caudate/putamen ratios
Regional loss patterns

DAT and Neurodegeneration

Pathophysiological Mechanisms

DAT loss in PD results from:

Synucleinopathy

Lewy body formation
Neuronal dysfunction
Terminal degeneration

Mitochondrial dysfunction

Complex I deficiency
Oxidative stress
Energy failure

Neuroinflammation

Microglial activation
Cytotoxic effects
Progressive loss

Neuroprotective Strategies

Potential DAT-protective approaches:

Monoamine oxidase-B inhibitors (selegiline, rasagiline)
Dopamine agonists
Neurotrophic factors
Gene therapy approaches

Research Directions

Biomarker Development

Early detection before motor symptoms
Disease progression markers
Treatment response predictors
At-risk population identification

Therapeutic Targets

DAT modulators for symptom control
Neuroprotective strategies
Gene therapy approaches
Cell replacement therapy monitoring

Summary

Dopamine transporters are essential membrane proteins that clear dopamine from the synaptic cleft, terminating dopaminergic neurotransmission. In Parkinsons disease, DAT loss in the nigrostriatal pathway is a hallmark of neurodegeneration. DAT neuroimaging has become invaluable for differential diagnosis, disease staging, and monitoring treatment responses. Understanding DAT biology provides insights into PD pathogenesis and opportunities for therapeutic intervention.

Background

The study of Dopamine Transporters In Parkinson'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

[Neuroanatomy Resources](https://pubmed.ncbi.nlm.nih.gov/)
[Neurodegeneration Research](https://www.alzforum.org/)

Pathway Diagram

The following diagram shows the key molecular relationships involving Dopamine Transporters in Parkinson's Disease discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →